Retatrutide is an investigational single-molecule agonist that engages three metabolic receptors at once. This overview summarizes what peer-reviewed phase 2 research reports about its effects on body weight, glucose handling and liver fat in human study populations, and where the evidence still stops.

What retatrutide is

Retatrutide, also identified in the literature by its development code LY3437943, is a synthetic peptide engineered to activate three receptors that normally respond to distinct gut and pancreatic hormones: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.¹ Because it reproduces the signaling of three hormones in one molecule, investigators describe it as a triple-hormone-receptor agonist, or triagonist. It sits within a broader research trajectory that began with single GLP-1 receptor agonists and progressed to dual GIP/GLP-1 agents such as tirzepatide.⁷

The scientific interest in adding glucagon-receptor activity is what separates retatrutide from earlier incretin research tools. Glucagon signaling is classically associated with raising blood glucose, but a growing body of work has re-examined its role in energy expenditure, hepatic lipid handling and appetite regulation.⁵ Pairing glucagon-receptor activity with GLP-1-receptor activity is intended, in the research rationale, to offset glucagon’s glucose-raising tendency while retaining its effects on energy metabolism. Laboratories comparing retatrutide with related agents such as tirzepatide and semaglutide are examining exactly how much the added glucagon arm contributes to the observed metabolic changes.

How triple-receptor agonism shapes metabolism

The three receptors retatrutide engages are physiologically distinct, and decades of incretin research describe their separate contributions. Understanding the reported effects of the molecule requires looking at each arm.

The GLP-1 arm

GLP-1 receptor activation is associated with glucose-dependent insulin secretion, slowed gastric emptying, suppression of glucagon release after meals, and central signaling linked to satiety. In foundational incretin physiology reviews, sustained GLP-1-receptor activation is associated with reduced food intake and weight loss in both preclinical and clinical models.⁴ This arm is the most extensively characterized of the three and anchors the appetite-related signaling attributed to retatrutide.

The GIP arm

GIP is the other principal incretin. Like GLP-1, it acts on pancreatic beta cells to potentiate glucose-dependent insulin secretion, but it also exerts direct effects on adipose tissue and energy storage.⁴ The role of GIP-receptor agonism in body-weight regulation has been debated in the literature, yet dual GIP/GLP-1 research established that combining the two incretin signals produced greater metabolic changes than GLP-1 signaling alone.⁷

The glucagon arm

Glucagon-receptor signaling is the differentiating component. Preclinical studies of glucagon/GLP-1 dual agonists report increased thermogenesis in brown adipose tissue, stimulation of lipolysis and fatty-acid oxidation, and reduced hepatic lipid accumulation in rodent models.⁶ Mechanistic reviews of glucagon biology attribute to it a role in hepatic mitochondrial fat oxidation, energy expenditure and reduced caloric intake, alongside its established glucose-raising action.⁵ In retatrutide, the intent is that GLP-1-driven insulin secretion counterbalances glucagon’s hyperglycemic tendency, leaving its lipid- and energy-related effects available for study.

Body-weight and adiposity findings

The most cited human data come from a phase 2, double-blind, randomized, placebo-controlled trial in adults with obesity, published in The New England Journal of Medicine.¹ The trial enrolled 338 adults and assigned them to placebo or one of several retatrutide dose regimens administered subcutaneously once weekly for 48 weeks. The primary endpoint was percentage change in body weight at 24 weeks.

At 24 weeks, least-squares mean body-weight change in the retatrutide groups ranged from −7.2% at 1 mg to −17.5% at 12 mg, compared with −1.6% for placebo. At 48 weeks, the change reached −24.2% in the 12 mg group versus −2.1% for placebo. Among participants receiving 12 mg, the trial reported that 100% achieved at least 5% weight reduction, 93% achieved at least 10%, and 83% achieved at least 15% at 48 weeks.¹ These are trial-reported outcomes in a controlled research population, not projections for any individual.

The reported reductions were dose-dependent and were accompanied by decreases in waist circumference and abdominal fat measures. Because the study period was 48 weeks, the durability of these changes beyond one year is not established by this trial and remains a question for the ongoing phase 3 program.

Glycemic findings in type 2 diabetes research

A separate phase 2 trial, published in The Lancet, examined retatrutide in adults with type 2 diabetes across a range of doses, using both a placebo and an active comparator (dulaglutide 1.5 mg).² The primary endpoint was change in glycated hemoglobin (HbA_1c) at 24 weeks.

At 24 weeks, HbA_1c reductions with retatrutide reached approximately −2.0% in the 12 mg group, compared with essentially no change on placebo and roughly −1.4% with dulaglutide. HbA_1c reductions were statistically greater than placebo in all but the lowest dose group, and greater than the active comparator in the higher-dose retatrutide groups.² Body weight also declined dose-dependently in this diabetes population, by up to roughly 17% at 36 weeks. The authors concluded that these phase 2 data informed dose selection for phase 3 and characterized the tolerability profile as consistent with GLP-1 and GIP/GLP-1 receptor agonists.

Liver fat and the MASLD substudy

One of the more distinctive datasets comes from a prespecified substudy of the obesity trial, published in Nature Medicine, that enrolled participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat.³ The substudy randomized 98 participants and measured relative change in liver fat, assessed by imaging, at 24 weeks.

The mean relative change in liver fat from baseline at 24 weeks was −42.9% at 1 mg, −57.0% at 4 mg, −81.4% at 8 mg and −82.4% at 12 mg, versus +0.3% with placebo, with all retatrutide arms differing significantly from placebo.³ Normal liver fat, defined as below 5%, was reached by 27%, 52%, 79% and 86% of participants across the ascending dose groups, and by none in the placebo group. The authors reported that liver-fat reductions were significantly related to changes in body weight, abdominal fat, and measures associated with insulin sensitivity and lipid metabolism.

These findings have positioned triple agonism as a candidate of interest in MASLD pharmacology reviews, which situate retatrutide within an expanding pipeline of glucagon-containing multi-agonists alongside agents with existing regulatory approval for steatotic liver disease.⁸ Importantly, this substudy measured liver fat content by imaging rather than fibrosis by biopsy, so histological endpoints for steatohepatitis are not established by this dataset.

Cardiometabolic and lipid markers

Across the phase 2 trials, investigators reported dose-related changes in a range of cardiometabolic measures beyond weight and glucose. The table below summarizes the direction of change reported in the published obesity and diabetes studies; magnitudes were dose-dependent and are drawn from controlled research populations.

The heart-rate signal is worth isolating: the obesity trial reported dose-dependent increases in heart rate that peaked around week 24 and declined thereafter.¹ This is a recognized pattern with incretin-based agents and is one reason cardiovascular monitoring features prominently in the design of later-stage trials. The lipid and blood-pressure movements reported in the substudy accompanied, and were statistically linked to, the reductions in body weight and adiposity rather than being demonstrably independent of them.³

Tolerability signals and evidence limits

Across the phase 2 trials, the most frequently reported adverse events in retatrutide groups were gastrointestinal, including nausea, diarrhea, vomiting and constipation.¹ These events were dose-related, were mostly mild to moderate in the reported severity grading, and were partially mitigated when treatment started at a 2 mg rather than a 4 mg dose. The obesity trial reported no hepatotoxic signal over its 48-week period, and the diabetes trial reported no severe hypoglycemia and no deaths.¹²

Several limits bound what these datasets can support. All are phase 2, with study durations of 36 to 48 weeks and sample sizes in the hundreds. They were designed to characterize dose-response, efficacy signals and short-term tolerability, not long-term outcomes such as cardiovascular events, or histological reversal of steatohepatitis. Retatrutide is investigational and is not an approved medicine; MASLD pharmacology reviews as of 2026 continue to describe it as a pipeline agent advancing through phase 3 development.⁸ For laboratories, this makes retatrutide a compelling reference compound for mechanistic comparison, while the clinical picture remains open.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.